IDR
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
IDRBench: Understanding the Capability of Large Language Models on Interdisciplinary Research
arXiv:2507.15736v3 Announce Type: replace Abstract: Innovation is a key driving force of human civilization. As the body of knowledge has grown considerably, bridging knowledge across different disciplines, where significant innovation often emerges, has become increasingly challenging. The recent advancements in machine learning models, particularly Large Language Models (LLMs), have provided effective access to extensive knowledge sources and shown impressive abilities in reasoning,...
DNA repair enzyme uses one-dimensional sliding to detect key sites, researchers reveal
DNA repair enzyme uses one-dimensional sliding to detect key sites, researchers reveal Sadie Harley Scientific Editor Robert Egan Associate Editor DNA is the blueprint of the human body. However, tens of thousands of DNA lesions occur in our bodies every day. In particular, if "apurinic/apyrimidinic sites" (AP sites, damaged sites where one letter of DNA information has been erased) are not properly repaired, they can lead to cancer and aging.
Scientists uncover RNA's hidden role as protein chaperone
Scientists uncover RNA's hidden role as protein chaperone Gaby Clark Scientific Editor Andrew Zinin Lead Editor Proteins are how cells get work done. They carry out nearly every important cellular task, from ferrying messages to controlling which genes are turned on or off. And in order for proteins to perform their various roles, the strings of amino acids that make them up need to be folded into the correct shape.
Molecular glue degraders of HuR suppress BRAF-mutant colorectal cancer
Abstract BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all patients with colorectal cancer (CRC), and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as encorafenib are ineffective due to MAPK pathway reactivation driven by BRAF dimerization. Combined inhibition of BRAF and EGFR, although approved therapies, results in short survival benefits and frequent treatment resistance and relapse1,2,3.